Antioxidants & Redox Signaling

Editor-in-Chief: Chandan K. Sen, PhD

ISSN: 1523-0864 | Online ISSN: 1557-7716 | 36 Issues Annually | Current Volume: 40

Impact Factor: 6.6* *2022 Journal Citation Reports™ (Clarivate, 2023)

CiteScore™: 14.5

The leading peer-reviewed journal dedicated to understanding of the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease, exploring key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics.

Search Subscribe/Renew Recommend This Title Sign Up for TOC Alerts View Submission Instructions Share with a Colleague

Announcements

Congratulations to Editorial Board Member Gregg L. Semenza, Professor of Genetic Medicine at The Johns Hopkins University School of Medicine! Dr. Semenza was jointly awarded the Nobel Prize in Physiology or Medicine with two other scientists, William G. Kaelin Jr. and Peter J. Ratcliffe, for their collective work on how cells sense oxygen and adapt to changes in oxygen availability. Dr. Semenza discovered the Hypoxia Inducible Factor-1 (HIF-1) transcriptional complex in 1995 and has since then demonstrated the importance of this pathway in maintaining cellular oxygen homeostasis and in the pathology of cancer, cerebral and myocardial ischemia and chronic lung disease.
CALL FOR PAPERS: Zero Submission Fees, Rapid Review
Learn More
RFS Awards in Science Winner

Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS Awards in Science for Antioxidants & Redox Signaling has selected Paula I. Moreira, PhD who co-authored Hypoxic Preconditioning Averts Sporadic Alzheimer's Disase-Like Phenotype in Rats: A Focus on Mitochondria.

View RFS Awards in Science Book

Aims & Scope

Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.

ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.

ARS coverage includes:

ROS/RNS as messengers
Gaseous signal transducers
Hypoxia and tissue oxygenation
microRNA
Prokaryotic systems
Lessons from plant biology

ARS is under the editorial leadership of Editor-in-Chief Chandan K. Sen, PhD, Indiana University School of Medicine, and other leading investigators. View the entire editorial board.

Audience: Cell biologists, molecular biologists, biochemists, medical researchers, and nutritionists, among others.

ARS provides "Instant Online" publication 72 hours after acceptance.
Average time to first decision: 16 days
Average time to triage decision: 48 hours

Indexing/Abstracting:

PubMed/MEDLINE
PubMed Central
Web of Science: Science Citation Index Expanded™ (SCIE)
Scopus
Current Contents®/Life Sciences
Biological Abstracts
BIOSIS Citation Index™
Journal Citation Reports/Science Edition
EMBASE/Excerpta Medica
Chemical Abstracts
ProQuest databases
SafetyLit
BenchSci

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.